ライフサイエンスコーパス: early phase

1 differences in uOR BP(ND) at resting state (early phase).

2 ated corticospinal projection fields in this early phase.

3 tion - the epitranscriptome - is still in an early phase.

4 e how networks and support evolve during the early phase.

5 ly induces type I interferon response in the early phase.

6 he larger degree of tracer clearance in this early phase.

7 he larger degree of tracer clearance in this early phase.

8 lvement of the striosomal compartment in the early phase.

9 n cognitive deficits of schizophrenia in its early phases.

10 ysis of the stroke hazard rate identified an early phase (0-10 days; 4.1% of strokes) and a late phas

11 nical rationale was provided, the results of early phase 1 and 2 clinical trials have been quite disa

12 In comparison with glucose metabolism, early-phase (11)C-DED and (11)C-PiB perfusion appear to

13 In this multitracer PET study, early-phase (11)C-DED and (11)C-Pittsburgh compound B ((

14 Together with a perfusion-weighted early-phase acquisition ((18)F-FDG PET-equivalent), a si

15 ctor associated with poor outcome during the early phase after dMCS (hazard ratio, 1.69 [1.37-2.09];

16 Global IL-6 inhibition in the early phase after fracture reduced systemic inflammation

17 into the fracture hematoma, both seen in the early phase after fracture, as well as a compromised fra

18 hages than the WT MDSC/BMP4/GFP cells in the early phase after injury.

19 he expected inflammatory response during the early phase after injury.

20 redict an increased risk of rejection in the early phase after renal transplantation.

21 y physiology of the nonculprit artery in the early phase after STEMI and determine the real prevalenc

22 nation of skin cells and immune cells in the early phase after wounding.

23 yeloma progression with clonal sweeps in the early phase and regional evolution in advanced disease.

24 earch strategy yielded 11 studies (9 smaller early-phase and 2 larger outcome trials).

25 ease, inclusion of a separate cohort in both early-phase and later-phase trials is recommended, if CN

26 Meal-related 30-minute (early phase) and 180-minute incremental area under the c

27 ntial loss of distinct striatal areas in the early phase, and investigate whether iron accumulation i

28 dication are proving more difficult than the early phases, and the development of effective drugs and

29 aging tasks at two time points; first in the early phase ( approximately 2 weeks) and then approximat

30 hypofluorescence in the macular area in the early phase, as well as increasing focal hyperfluorescen

31 ter meal responses except for an increase in early phase C-peptide (P = 0.04).

32 nd the establishment of the magnitude of the early-phase cardiovascular disease risk in these childre

33 To improve this figure, several early phase clinical trials combining novel immunotherap

34 The Ivy Foundation Early Phase Clinical Trials Consortium conducted a rando

35 Gene therapy has been advanced to early phase clinical trials for the replacement of G6Pas

36 Early phase clinical trials have demonstrated good thera

37 A and mTOR, are currently being evaluated in early phase clinical trials in children with high-risk M

38 Recent advances in preclinical studies and early phase clinical trials offer renewed promise for im

39 ts with a broad range of advanced cancers to early phase clinical trials on the basis of analysis of

40 e useful in monitoring treatment response in early phase clinical trials.

41 analyzed 67 heavily pretreated patients on 3 early phase clinical trials.

42 EZH2 small molecule inhibitors are entering early phase clinical trials.

43 ase inhibitors are currently being tested in early phase clinical trials.

44 Early-phase clinical evaluation of CMP-001 and anti-PD-1

45 lation between submucosal mast cells and the early-phase clinical response (r = 0.79, P = .007) and a

46 Preclinical and early-phase clinical studies have found specific pathway

47 Notably, the early-phase clinical symptoms in the conjunctiva after O

48 We conducted an early-phase clinical trial (NCT02415881) and previously

49 ion of novel drug targets, interpretation of early-phase clinical trial data, and development of pred

50 leagues discuss the potential for innovative early-phase clinical trial methods and technologies to r

51 Early-phase clinical trial results have demonstrated the

52 Finally, we simulated an early-phase clinical trial to demonstrate that batched a

53 therapies for this group of disorders are in early-phase clinical trial, realistic expectations are t

54 elded encouraging preliminary results in two early-phase clinical trials and is currently being evalu

55 els of cancers and autoimmune disorders, and early-phase clinical trials are underway to determine th

56 s manufacturers of investigational drugs for early-phase clinical trials engaged in industry partners

57 Early-phase clinical trials evaluating CD8(+) T cell-eli

58 nically useful OCT instrument coincided with early-phase clinical trials of a drug that would become

59 Indeed, early-phase clinical trials of T(reg) cell therapy have

60 hat are supported by preclinical studies and early-phase clinical trials suggesting that these approa

61 Early-phase clinical trials targeting some of these mole

62 here have been glimmers of hope from several early-phase clinical trials that suggest that sufficient

63 Most studies identified were early-phase clinical trials that were small in size, sho

64 t, some key considerations for the design of early-phase clinical trials using agents that specifical

65 nst HER3 that has shown promising results in early-phase clinical trials, but an optimal target popul

66 In early-phase clinical trials, chemotherapeutic agents tar

67 Despite promising preclinical results and early-phase clinical trials, the goal of developing safe

68 rities across the world and those undergoing early-phase clinical trials.

69 nd point in pro-cognitive drug discovery and early-phase clinical trials.

70 ancer therapeutic in preclinical studies and early-phase clinical trials.

71 pharmacodynamic biomarkers is increasing in early-phase clinical trials.

72 promising therapeutic candidate currently in early-phase clinical trials.

73 Our early-phase data showed that administration of ipilimuma

74 Our early-phase data suggested that children with neurofibro

75 at became significantly expressed during the Early phase (day 0 and 1 post-TBI).

76 C-MS analyses can provide key information in early phase development and deliver multiple study end p

77 and molecular changes characteristic of the early phase disease.

78 itant, grooming progresses gradually from an early phase dominated by anterior cleaning to a later ph

79 proach seeks to improve too-often-misleading early-phase drug development methods by incorporating bi

80 e of robust surrogate markers may accelerate early-phase drug development.

81 blishes a novel role for IL-27 in regulating early-phase effector functions of NK cells during influe

82 ion myeloid cell-derived IL-27 regulates the early-phase effector functions of NK cells in the bronch

83 sruption of this signaling axis impaired the early-phase expression of IRF3 target genes and the indu

84 Although increasingly used in the early phase following traumatic brain injury, the progno

85 The AMI group had higher unadjusted early phase hazard (hazard ratio [HR]: 1.24; p = 0.04) a

86 Animal as well as early phase human studies with aptamers have not shown s

87 advance this combinatorial treatment toward early-phase human trials.

88 Many have now developed a role in the very early phase (hyperacute units) plus outreach for patient

89 ug-drug interaction (DDI) risk assessment in early phase I clinical trials.

90 he adult heart in two distinctive phases: an early phase immediately after MI and long-term protectio

91 ALDI), (iii) MALDI-TOF MS identification and early phase implementation of TLA (TLA1), and (iv) MALDI

92 lementation problems encountered during this early phase in the pandemic, and try to define future di

93 or effective therapeutic interventions at an early phase in this specific patient population.

94 nferred to fill gaps in our understanding of early phases in the breeding cycle of theropods.

95 is effective in modulating body fat, SCFAs, early-phase insulin and GLP-1 secretion and the gut micr

96 y novel genetic variants associated with the early-phase insulin response to a liquid mixed meal by a

97 The early-phase insulin response was defined as the differen

98 Early-phase insulin secretion is a determinant of postpr

99 ents in functional islet mass and associated early-phase insulin secretion, which with decreased incr

100 rs505922:C allele may be caused by decreased early-phase insulin secretion.

101 Acetate and early-phase insulin, C-peptide and glucagon-like peptide

102 al and physiological mechanisms to target in early phase intervention development.

103 dations for how the inclusion of children in early-phase investigational cancer drug trials might be

104 tification ratio of AMPAR EPSCs and elevated early-phase long term potentiation (LTP).

105 In the early phase, low-level MyD88-dependent chemokine express

106 compete earlier-phase strains, although four early-phase members persist.

107 obust and meaningful response end points for early-phase metastatic castration-resistant prostate can

108 e of the inverse-Compton emission during the early phase of a supernova.

109 depression and cardiovascular status at the early phase of ACS.

110 al kidney function is exceptional during the early phase of acute circulatory failure.

111 hibition that may confer benefits during the early phase of acute coronary syndrome.

112 fector cell population most prominent in the early phase of acute viral and bacterial infections and

113 g model on transcriptional regulation in the early phase of adipogenesis and highlight the need of st

114 induction of C/EBPbeta and C/EBPdelta in the early phase of adipogenesis.

115 educing the inflammatory reaction during the early phase of AILI.

116 owing their initial establishment during the early phase of AIT.

117 Wwe demonstrate that during the early phase of AKI either blockade of the proinflammator

118 he role of infiltrating monocytes during the early phase of ALF is still ambiguous.

119 nctional IgE-blocking IgG1 antibodies in the early phase of allergy treatment.

120 1 receptor (IL-21R) blocking antibody on the early phase of allograft rejection in a humanized skin t

121 ctivity is elevated, as, for example, in the early phase of Alzheimer's disease.

122 in, we show that blockade of IL-12p40 in the early phase of aneurysm development suppresses macrophag

123 Diffuse pulmonary infiltrates in early phase of anti-tuberculosis treatment was related w

124 y incorporating the short-read data into the early phase of assembly, during the read correction step

125 ation of retinal spike efficacy suggests the early phase of augmented suppression involves local thal

126 t of Il1rl2 (-/-) mice with IL-23 during the early phase of C. rodentium infection rescued IL-22 prod

127 Based on review of MITS from the early phase of CHAMPS, the CPL has developed standardize

128 s derive from mature macrophages in the very early phase of CNS vascular development, which in turn a

129 t (cofactor) function of FV that targets the early phase of coagulation before prothrombinase assembl

130 el environment presented during a vulnerable early phase of consolidation.

131 ng that AMPAR diffusion is important for the early phase of contextual learning.

132 dence for remnant magnetism might suggest an early phase of crustal spreading.

133 e demonstrated that GBP1 acted mainly on the early phase of CSFV replication and inhibited the transl

134 get dsi-RNA to female Cx. pipiens during the early phase of diapause.

135 -activated receptor gamma (PPARgamma) in the early phase of differentiation.

136 ose To propose and validate criteria for the early phase of DISH by using CT data from two large-scal

137 ing and triaging new hA3R antagonists in the early phase of drug discovery.

138 hondria Ca(2+) transfer increases during the early phase of ER stress induced by tunicamycin as an ad

139 R321 inhibits only the early phase of extracellular signal-regulated kinase 1/2

140 tion that high levels of beta-catenin in the early phase of fracture healing in old animals slows ost

141 and yogurt samples were digested within the early phase of gastric digestion.

142 sis is angiogenin, which is expressed in the early phase of healing in oral tissue engineering strate

143 at neutrophils play an essential role in the early phase of hepatic ischemia-reperfusion injury and d

144 y which neutrophils are recruited during the early phase of histamine-induced inflammation involves t

145 se is likely to be more effective during the early phase of HIV-1 infection and diminishes at the lat

146 ved the presence of post-entry blocks to the early phase of HIV-1 infection in peripheral blood lymph

147 innate defenses by herpesviruses during the early phase of host colonization indicates that highly s

148 bundance in these humanized mice mirrors the early phase of HTLV-1 infection in humans, providing a u

149 elta cells, suggesting that Hir1 impacts the early phase of hyphal initiation.

150 formation regarding perceived support in the early phase of illness.

151 by promoting spirochete proliferation in the early phase of infection in the skin.

152 Whereas levels remained normal during the early phase of infection when the virus was actively rep

153 hly comparable to those of adults during the early phase of infection, despite distinct differences i

154 icient T cells are hyperactivated during the early phase of infection, exhibiting increased prolifera

155 transferred TCR-transgenic cells during the early phase of infection, suggesting that T cell priming

156 151 and EGFR and the HPV16 capsid during the early phase of infection.

157 egan antiretroviral therapy (ART) during the early phase of infection.

158 ba on human monocytes/macrophages during the early phase of infection.

159 fter entry, suggesting it is required in the early phase of infection.

160 secretion of other cytokines involved in the early phase of inflammation, including IL-12, eotaxin, R

161 The early phase of influenza infection occurs in the upper r

162 We conclude that the early phase of infraspinatus muscle degeneration after t

163 The early phase of injury causes loss of dendritic spines an

164 In the early phase of injury, the rate of myelin clearance was

165 de that visual development progresses via an early phase of instructive plasticity, when the specific

166 al distribution of the microbiota during the early phase of its administration.

167 susceptible target cell, HIV-1 completes the early phase of its life cycle upon integration of revers

168 or cause of renal failure, especially at the early phase of kidney transplant when ischemia-reperfusi

169 e rapidly and directly induced by RTA in the early phase of KSHV lytic reactivation.

170 In addition, early phase of learning was associated with increased ac

171 le-membrane phagophore is a key event in the early phase of macroautophagy, but can also occur on sin

172 peeds intracellular acidification during the early phase of metabolic acidosis (MAc), not just in neu

173 The game changers in the early phase of my career were informal mentors, open sci

174 Prefibrotic myelofibrosis represents an early phase of myelofibrosis, and is characterized by gr

175 ase gene is induced by Nod factor during the early phase of nodule initiation.

176 atic cancer development: an AGO2-independent early phase of PanIN formation reliant on EGFR-RAS signa

177 pensatory mechanisms are involved during the early phase of Parkinson's disease (PD) to delay the exp

178 reduced left prefrontal activity during the early phase of perturbation and increased right middle t

179 smission in the pathophysiology of the acute early phase of psychotic illnesses.

180 Vpr acts quickly during the early phase of replication and induces the degradation o

181 uxin-dependent inhibition of root growth and early phase of root gravitropism.

182 tients with SBP revealed loss of LPMs in the early phase of SBP, but levels increased after treatment

183 obutyric acid) levels have been found in the early phase of schizophrenia and may underlie cognitive

184 ot proNeu2s, selectively expanded during the early phase of sepsis at the expense of monocytes.

185 icial effects of O-GlcNAc stimulation at the early phase of septic shock.

186 would be impaired, and BP increased, in the early phase of T1DM.

187 n (4 x 10(6) pg.L(water)(-1)) obtained at an early phase of the bloom.

188 During the early phase of the coronavirus disease 2019 (COVID-19) p

189 and Development (OECD) countries during the early phase of the coronavirus disease 2019 (COVID-19) p

190 rk by social media, rumors, and panic in the early phase of the COVID-19 pandemic." In this article,

191 ients suggest the involvement of FB from the early phase of the disease.

192 tients with leptospirosis, especially at the early phase of the disease.

193 rdiovascular protective effect of PCR in the early phase of the disease.

194 , while are only anecdotally reported in the early phase of the disease.

195 raveling cases represented a priority in the early phase of the epidemic.

196 onstrates considerable complexity during the early phase of the infection that can influence the abil

197 We found at early phase of the infection, PFOS inhibited the expansi

198 on of nociceptor terminals did not alter the early phase of the inflammatory response to UVB, but it

199 North Atlantic freshwater forcing during the early phase of the last deglaciation, NADW nearly collap

200 a on COVID-19 cases outside China during the early phase of the pandemic and used them to predict tre

201 This study is restricted to the early phase of the pandemic, when China was the only lar

202 ing the rise in coastal N sources during the early phase of the Pearl River estuary urbanization.

203 ession pattern to the PH than the PVL at the early phase of the regeneration.

204 Depressive symptoms in the early phase of the study corresponding to midlife, even

205 urated after three stimuli and dominated the early phase of the train EPSC; and the other, with small

206 d with greater total RNA accumulation in the early phase of the training period, suggesting that ribo

207 sential roles at virtually every step in the early phase of the viral life cycle.

208 , transcription, and DNA condensation in the early phase of the viral life-cycle.

209 Here, we monitor the early phase of this cascade at high spatiotemporal resol

210 The early phase of this decline in coronary heart disease an

211 The early phase of TLR signaling and the TLR-dependent secre

212 reactivation in ART-treated macaques in the early phase of treatment.

213 l immune responses in mice by simulating the early phase of viral infection without concomitant exces

214 cute inflammatory responses initiated in the early phase of viral URI contribute to preventing the de

215 ion of acute upregulation of miR-200c at the early phase of wound healing in aged skin.

216 nner after myocardial infarction, beyond the early phase of wound healing, and exhibited proinflammat

217 PNPLA3 gene and protein increases during the early phases of activation and remains elevated in fully

218 the heterochromatic ribosomal DNA during the early phases of aging, followed by sustained loss of sil

219 mulated per-capita CO2 emissions from LUC in early phases of agricultural development, humans emerge

220 ct for causing cognitive deficits during the early phases of Alzheimer's disease (AD).

221 sceptible individuals, especially during the early phases of an epidemic, takes place over a (possibl

222 nterface stabilization during mixing and the early phases of baking.

223 eta-catenin signaling is responsible for the early phases of brain vascularization and BBB differenti

224 ight partially compensate myelin loss in the early phases of demyelinating disorders, this spontaneou

225 ever, the timing and basis of its origin and early phases of dispersal remain poorly documented.

226 Recent advances in the early phases of drug discovery including hit finding, ta

227 lecting new hCB1 receptor antagonists in the early phases of drug discovery.

228 ric antigen receptor (CAR) expression during early phases of ex vivo generation of lymphoid progenito

229 ant does not synthesize detectable SB during early phases of growth.

230 nt ligand upregulation, thus indicating that early phases of HCMV infection are involved in ligand in

231 However, early phases of hematopoietic reconstitution following b

232 specimen processing optimization during the early phases of implementation planning for NAATs in the

233 These early phases of infection are notably vulnerable to supp

234 vitro studies revealed that during the very early phases of infection, GSH depletion and the downreg

235 ligand (CCL)20, which is up-regulated during early phases of inflammation.

236 ntify pathways and genes likely to drive the early phases of leukaemogenesis.

237 but LAV alone is an insensitive biomarker of early phases of LVDD, because the LA may take time to re

238 d to mitotic spindle poles (MSPs) during the early phases of mitosis where it colocalizes with its pa

239 es of results that should be reported in the early phases of molecular biomarker development, discuss

240 Although early phases of neural development were unaltered, Slc7a

241 for improving cognitive function during the early phases of neurodegenerative diseases.

242 Metoprolol acts during early phases of neutrophil recruitment by impairing stru

243 caudate dopaminergic dysfunction in the very early phases of PD (<2 years from diagnosis) using (123)

244 f rTIMP-3 for reduction of I/R injury in the early phases of post-MI remodeling.

245 vel, an upregulation of ERK signaling during early phases of postnatal development, but not in the ad

246 early as possible, its consideration in the early phases of rational chemical design is therefore ch

247 In the early phases of sepsis, monocytes infiltrate the brain w

248 lators, cytokinin also is accumulated during early phases of symbiotic interaction, but the pathways

249 he effect of differential methylation in the early phases of T2D pathology by a blood-based epigenome

250 fragments, including known genes involved in early phases of the adenoma-carcinoma sequence (such as,

251 nalyses (and their communication) during the early phases of the COVID-19 outbreak, as seen through t

252 he detection of executive deficits since the early phases of the disease.

253 when distinguishing between the late and the early phases of the experiment.

254 re actively displaced by female kicks in the early phases of the interaction, while flight cessation

255 lthough inflammation is necessary during the early phases of tissue repair, persistent inflammation c

256 are present in the wounded cornea during the early phases of wound healing.

257 Some are making the transition into early-phase patient trials, but the lack of validated bi

258 thora of parameters that represents reliable early-phase PD biomarkers which can easily be measured a

259 liferation in the Aquilegia petal during the early phase (phase I) of spur development and also appea

260 hanisms that support cardiac function in the early phase post MI and identifying the processes that i

261 Acetylcholine administration in the early phase post-STEMI in patients with multivessel dise

262 Unlike the unidirectional late-to-early phase precession of place cells, bidirectional pha

263 tter assessment during RE procedures because early phases provide good mapping for superselective cat

264 an academic research center and included 82 early-phase psychosis patients (23 females; mean age [SD

265 n network morphology and clinical outcome in early-phase psychosis.

266 antipsychotic treatment in 81 patients with early-phase psychosis.

267 ship was observed for activation in both the early phase (r = 0.363, P = 0.03 one-tailed) and the lat

268 ng ligand (TRAIL) death receptors, promoting early-phase replication.

269 We previously described and characterized an early-phase restriction of HIV-1 and -2 replication in h

270 We included 83 patients with early phase schizophrenia and minimal exposure to antips

271 d mid- and late-phase but not VAMP2-mediated early-phase secretion.

272 the difference in safety between the smaller early-phase studies and the larger outcome studies.

273 While early-phase studies have supported potential use of vagu

274 As an early phase study, limitations include small patient num

275 shows potential as a treatment for MDD in an early phase study.

276 In a small, early-phase study involving men with severe hemophilia A

277 lly distinct phases of protein synthesis: an early phase that appears to prime LTM; and a later phase

278 arget gene expression and might be useful in early phase therapeutic trials to demonstrate target eng

279 In the early phase, there was also upward displacement of the e

280 Fa depletion studies revealed that transient early-phase TNFa signaling in Resolved mice promoted cle

281 ata support the application of ctDNA in this early phase trial setting where broad genomic profiling

282 issue of the JCI, Cohen et al. conducted an early phase trial to evaluate B cell maturation antigen-

283 Although some early-phase trial data are promising, reports of blindin

284 on when merited by evidence collected during early-phase trial investigations.

285 iscriminative performance that could used in early phase trials of ulcerative colitis.

286 This transformation has especially affected early phase trials, leading to the current situation in

287 ology have led to unprecedented responses in early phase trials, sometimes resulting in drug approval

288 h some novel compounds undergoing testing in early phase trials.

289 cytokine receptor and kinase signaling, and early-phase trials are investigating the potential of th

290 chimeric antigen receptor (CAR) T cells from early-phase trials in relapsed patients to a viable ther

291 Some early-phase trials of cell therapies suggest acceptable

292 sion of pediatric patients is appropriate in early-phase trials that assess dose, safety, and pharmac

293 all lymphocytic lymphoma (SLL) enrolled in 4 early-phase trials were pooled.

294 Early-phase trials with monoclonal antibodies targeting

295 titumour activity and manageable toxicity in early-phase trials.

296 elopment, with promising data available from early-phase trials.

297 NTRK3 gene fusions treated in three ongoing, early-phase trials.

298 The early phase was characterized by moderately sensitized g

299 tion with biologic response modifiers in the early phases, whereas in patients with the advanced stag

300 Whereas early-phase wound macrophages are essential for initiati